Epizyme Cash on Hand 2012-2022 | EPZM
Epizyme cash on hand from 2012 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Epizyme Annual Cash on Hand
(Millions of US $) |
| 2021 |
$177 |
| 2020 |
$374 |
| 2019 |
$381 |
| 2018 |
$240 |
| 2017 |
$276 |
| 2016 |
$242 |
| 2015 |
$208 |
| 2014 |
$190 |
| 2013 |
$124 |
| 2012 |
$98 |
| 2011 |
$33 |
Epizyme Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$200 |
| 2021-12-31 |
$177 |
| 2021-09-30 |
$221 |
| 2021-06-30 |
$244 |
| 2021-03-31 |
$299 |
| 2020-12-31 |
$374 |
| 2020-09-30 |
$280 |
| 2020-06-30 |
$322 |
| 2020-03-31 |
$376 |
| 2019-12-31 |
$381 |
| 2019-09-30 |
$293 |
| 2019-06-30 |
$331 |
| 2019-03-31 |
$371 |
| 2018-12-31 |
$240 |
| 2018-09-30 |
$181 |
| 2018-06-30 |
$216 |
| 2018-03-31 |
$248 |
| 2017-12-31 |
$276 |
| 2017-09-30 |
$307 |
| 2017-06-30 |
$193 |
| 2017-03-31 |
$211 |
| 2016-12-31 |
$242 |
| 2016-09-30 |
$263 |
| 2016-06-30 |
$289 |
| 2016-03-31 |
$313 |
| 2015-12-31 |
$208 |
| 2015-09-30 |
$230 |
| 2015-06-30 |
$237 |
| 2015-03-31 |
$245 |
| 2014-12-31 |
$190 |
| 2014-09-30 |
$212 |
| 2014-06-30 |
$230 |
| 2014-03-31 |
$237 |
| 2013-12-31 |
$124 |
| 2013-09-30 |
$140 |
| 2013-06-30 |
$149 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2011-12-31 |
$33 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.244B |
$0.037B |
|
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
|
